

Erratum to: Efficacy and Safety of Olmesartan Medoxomil 40 mg/Hydrochlorothiazide 12.5 mg Combination Therapy versus Olmesartan Medoxomil 40 mg Monotherapy in Patients with Moderate to Severe Hypertension

A Randomized, Double-Blind, Parallel-Group, Multicentre, Multinational, Phase III Study

Roberto Fogari · Stefano Taddei ·
Merete Holm-Bentzen · Jacek Baszak ·
Lorenzo Melani · Kai Schumacher

Published online: 20 December 2012
© Springer International Publishing Switzerland 2012

**Erratum to: Clin Drug Investig (2010) 30(9):581–597
DOI 10.2165/11536710-000000000-00000**

Page 587, Figure 2, right-hand side of the figure, third box from bottom, which previously read:

“OM/HCTZ 40 mg
n = 129”

should read:
“OM 40 mg
n = 129”

Page 587, Figure 2, right-hand side of the figure, first box from bottom, which previously read:

“Completed
OM/HCTZ 40 mg
n = 128”

should read:
“Completed
OM 40 mg
n = 128”

The online version of the original article can be found under
doi:[10.2165/11536710-000000000-00000](https://doi.org/10.2165/11536710-000000000-00000).

R. Fogari (✉)
Medical Clinic II-Policlinic San Matteo, University of Pavia,
Pavia, Italy
e-mail: r.fogari@smatteo.pv.it

S. Taddei
Department of Internal Medicine, University of Pisa, Pisa, Italy

M. Holm-Bentzen
CCBR Clinical Research Center A/S, Ballerup, Denmark

J. Baszak
Top-Medical Sp. z o.o., Lublin, Poland

L. Melani
Clinical Research Department, Menarini Ricerche SpA,
Florence, Italy

K. Schumacher
Clinical Research Department, Berlin-Chemie AG/Menarini,
Berlin, Germany